BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization … – Wall Street Journal
|
BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization …
Wall Street Journal Secondary objectives include assessment of the efficacy of BL-8040 in mobilizing stem cells as a stand-alone therapy, as well as monitoring the pharmacokinetic profile of the drug. This part will be performed in up to 4 cohorts, with 8 healthy … |
